ClinicalTrials.gg
CompletedNCT00357279Updated Nov 4, 2015

Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease

A Phase 3 interventional study of denufosol tetrasodium (INS37217) Inhalation Solution and Placebo - 0.9% w/v sodium chloride solution in Cystic Fibrosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2015-11-04.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
352
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.

Enrollment
2nd of 10
352 · median 68
Started
2006
the only one that year
Phase 3
3 of 10
none open now
Registered
5th of 10
by date

Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 2nd largest by enrollment, is the only one that started in 2006, is one of 3 in phase 3, and was the 5th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Cystic Fibrosis by Merck & Co., Inc as a file.
02

Study summary

The purpose of this trial is to evaluate the safety and effectiveness of a one dose strength of denufosol compared to placebo in patients with mild CF lung disease.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have confirmed diagnosis of cystic fibrosis
  • Have of greater than or equal to 75% of predicted normal for age, gender, and height
  • Be able to reproducibly perform spirometry maneuvers
  • Be clinically stable for at least 4 weeks prior to screening

Exclusion criteria

Exclusion Criteria:

  • Have abnormal renal or liver function
  • Have chest x-ray at screening suggesting active pulmonary disease
  • Be colonized with Burkholderia cepacia
  • Have had a lung transplant
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
352 participants (actual)

Study arms

  • Placebo comparator
    1

    Placebo

    Drug: Placebo - 0.9% w/v sodium chloride solution

  • Experimental
    2

    Drug: denufosol tetrasodium (INS37217) Inhalation Solution

Interventions

  • DrugDenufosol tetrasodiumStudies of Denufosol tetrasodiumDenufosol tetrasodium pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.

  • DrugPlacebo - 0.9% w/v sodium chloride solution

    4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.

06

What researchers measure

Primary outcomes

  1. Change in lung function

    Time frame: 48 weeks

Secondary outcomes

  1. Pulmonary exacerbation

    Time frame: 48 weeks

  2. Requirements for concomitant CF medications

    Time frame: 48 weeks

  3. Quality of Life

    Time frame: 48 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Accurso FJ, Moss RB, Wilmott RW, Anbar RD, Schaberg AE, Durham TA, Ramsey BW; TIGER-1 Investigator Study Group. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am J Respir Crit Care Med. 2011 Mar 1;183(5):627-34. doi: 10.1164/rccm.201008-1267OC. Epub 2010 Dec 17. PubMed 21169471 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2006
First posted
Jul 27, 2006
Start
Jul 2006
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results delay requested
Mar 24, 2011
Last update
Nov 4, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00357279
Responsible party
Sponsor
First posted
Jul 27, 2006
Start date
Jul 2006
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Nov 4, 2015
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denufosol tetrasodium

Start the discussion